Product Images Pemfexy

The text describes the survival probability of patients treated with two different chemotherapy regimens (Pemfexy + Cisplatin and Gemcitabine + Cisplatin) using a graph with survival time in months on the x-axis and percentage of patients surviving on the y-axis. The data also includes the number of patients at risk for each regimen at various time intervals.*

This is a table of data that compares two different treatments for cancer: Pemfexy + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The data includes the number of patients at risk for each treatment and their respective survival times in months.*

This appears to be a table showing survival probability and time for two treatment options (Pomfexy + Cisplatin and Gomeitabine + Cisplatin) in cancer patients. The data shows the number of patients at risk over time for each treatment option.*

The text describes the "Survival Probability" of patients who took "Pemfexy" and "Placebo" in a clinical trial over a period of months. The numbers represent the counts of the patients who were still alive during the given month out of the initial groups of patients - "441" patients who took Pemfexy and "222" patients who took Placebo. The final column shows the number of patients at risk.*

The text appears to be a table showing survival probability and survival time for two different groups (Pomfoxy and Placebo). The numbers in the table might represent the number of study participants who survived over a certain period of time, but without additional information, it is unclear how to interpret the numbers. The last two rows show some numbers that are not related to the table itself, but their meaning is not clear.*

This appears to be a table showing the survival probability and patients at risk in a clinical trial for Pemfexy compared to placebo. The table also includes survival time in months for the patients in each group.*

This appears to be a table showing survival probability and patients at risk for two different groups (Pemfoxy and Placebo) over a certain survival time period, which is measured in months. However, without more information about what these groups are or what the purpose of the data is, it is difficult to provide a more specific description.*

The text is a survival probability chart that shows the probability of survival over time (in months) for patients receiving two different treatments. The treatments are Pemfexy + Cispl and Cisplatin. The chart also includes the number of patients at risk for each treatment at different time intervals.*

This is a description of a drug with the NDC code 42367-531-33. The drug is called PEMFEAY, and it is a cytotoxic agent available in a multi-dose vial. The drug is meant for intravenous infusion after dilution, and it is important to use caution during handling and preparation. The recommended dosage can be found in the prescribing information, as well as information on dosing and dilution. The drug must be diluted further before administration and infused within 48 hours after preparation. The vial and the diluted solution should be refrigerated between 2°C and 8°C. The drug is marketed by Eagle Pharmaceuticals, Inc. as prescription-only.*